US preparing 100% pharmaceutical tariffs- FT

The Trump administration plans to impose 100% tariffs on certain imported pharmaceuticals, with the levies to be announced as soon as Thursday and applied to companies that have not struck deals with the White House. Tariffs will be capped based on imports from countries that have deals; Pfizer, AstraZeneca and Novo Nordisk have signed agreements, while non-compliant manufacturers face significant cost pressure and stronger incentives to onshore production.

Analysis

A headline tariff threat creates an immediate structural bifurcation across the pharma value chain: firms with credible US manufacturing footprints (or signed ‘de-risking’ deals) gain not only tariff insulation but practical pricing optionality, while those whose finished‑goods or APIs are >30–50% imported face margin compression or market-share loss unless they re-route supply within 6–36 months. This bifurcation will be amplified by limited US fill/finish and sterile‑manufacturing spare capacity — a 12–24 month window for meaningful volume migration is realistic because building validated sterile lines typically takes 12+ months and FDA inspections add unpredictable lag.

Second‑order winners include US CDMOs, API producers, and domestic logistics/freight providers able to absorb redirected flows; these winners will capture both incremental volumes and pricing power on contract terms (longer minimums, pass‑throughs for capex). Losers extend beyond branded names without US plants: small/mid biotech and specialty firms that source critical APIs abroad (thin margin buffers, single‑source suppliers) can see cash‑flow stress and discrete supply shocks that compress valuations more than headline tariff losses suggest.

Near‑term catalysts: White House announcements and country‑by‑country cap definitions will drive headline volatility in days; meaningful earnings and guidance impact will predominantly show in quarterly reports over 3–12 months as companies disclose exemptions, re‑routing costs, and capex plans. Reversal vectors are legal challenges, congressional constraints, or rapid multi‑firm deals with the Administration — any of which can materially shorten the disruption window.

Contrarian read: the market’s risk‑off kneejerk understates two offsetting dynamics — (1) many large multinationals already hedge supply risk and will accelerate negotiated concessions (limiting revenue hit), and (2) the policy actually creates concentrated, durable pricing power for US manufacturers and select CDMOs; as a result the net value transfer could be positive for a focused set of industrial suppliers even if headline pharma margins wobble.

Key Decisions for Investors

• Buy Catalent (CTLT) 6–9 month 30–45% OTM call spread (size 1–2% NAV): asymmetric way to own onshoring demand and fill/finish pricing power. R/R: limited premium vs multi‑month upside if contract volumes and minimums reprice; risk: option expires worthless if policy is paused or deals proliferate quickly.
• Add Thermo Fisher (TMO) long (allocate 2–4% NAV, hold 9–12 months): industrial supplier exposure to API/CDMO capex and analytics demand. R/R: modest downside defensiveness with 10–20% upside if broad onshoring accelerates; risk: already priced as defensive, so slower gamma.
• Long Pfizer (PFE) stock (12 months) and hedge by buying 6‑month puts on XBI (small‑cap biotech ETF) sized 20–30% of the equity position: expresses rotation to politically insulated large pharma vs import‑exposed small caps. R/R: PFE upside from political goodwill/stable US access, downside capped by put hedge on idiosyncratic small‑cap exposure; cost of hedge is the main P/L drag.
• Tactical protection: buy 3–6 month puts on SPDR S&P Pharmaceuticals ETF (XPH) as a short‑window hedge around White House announcements (size 0.5–1% NAV). Use this to limit headline‑driven downside while deciding on directional allocations once country caps and legal outcomes are clear.